EMD Serono Newsroom

To keep up with the latest news in real-time, subscribe to our email alerts, and follow us on Twitter, Facebook and LinkedIn. If you are a reporter and have questions about the company, please contact us

Latest News

 

May 20, 2019

GLUCOPHAGE® (metformin hydrochloride) was previously commercialized by Bristol-Myers Squibb (BMS) in the U.S., and BMS has decided to discontinue commercialization. Merck KGaA, Darmstadt, Germany...

May 16, 2019

Not intended for UK-based media New biomarker analyses for BAVENCIO®* (avelumab) in combination with axitinib in first-line renal cell carcinoma (RCC) Data presented across several modalities and...

May 14, 2019

Not intended for UK-based media BAVENCIO is the first anti-PD-L1 in combination with INLYTA approved by FDA for first-line treatment of patients with advanced renal cell carcinoma (RCC) Phase III...

May 10, 2019

EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced new 48-week results of the double-blind, randomized, placebo-controlled, Phase...

  All Press Releases